Genentech opens new $250M biologics manufacturing site in South San Francisco
30 Aug 2022
The company announced on Tuesday that it has opened the doors to its new $250 million manufacturing site for small-batch biologics in South San Francisco.
The site, called the “Clinical Supply Center,” will eventually make Genetech’s experimental drugs, the Roche subsidiary tells Endpoints News via email.
The 78,520 square-foot building took the company around two years to build as the company broke ground on the site just before the Covid-19 pandemic kicked off into high gear in February of 2020. The company expects medicine production to start next year, the company added in its email to Endpoints.
According to the company, the facility also plans to use fewer resources in the manufacturing process to reduce the environmental impact of the site.
This opening comes as Genentech has been making several plays earlier in the month. The company recently shelled out $80 million in upfront cash to license Kiniksa’s vixarelimab and lead it into new clinical trials. Researchers plan to launch Phase II studies in idiopathic pulmonary fibrosis/interstitial lung disease sometime later this year.
The company, along with Roche, also placed a $60 million bet to partner with Jemincare to push forward a new program for prostate cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.